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Fibroblast growth factor-23 (FGF23) is critical for phosphate and vitamin D homeostasis.  
Cellular and molecular mechanisms underlying FGF23 production remain poorly defined.  The 
extra-large Gα subunit (XLαs) is a variant of the stimulatory G protein alpha-subunit (Gsα), 
which mediates the stimulatory action of parathyroid hormone in skeletal FGF23 production.  
XLαs ablation causes diminished FGF23 levels in early postnatal mice.  Herein we found that 
plasma FGF23 levels were comparable in adult XLαs knockout (XLKO) and WT littermates.  
Upon adenine-rich diet-induced renal injury, a model of chronic kidney disease, both mice 
showed increased levels of plasma FGF23. Unexpectedly, XLKO mice had markedly higher 
FGF23 levels than WT mice, with higher BUN and more severe tubulopathy.  FGF23 mRNA 
levels increased substantially in bone and bone marrow in both genotypes; however, the levels in 
bone were markedly higher than in bone marrow.  In XLKO mice, a positive linear correlation 
was observed between plasma FGF23 and bone, but not bone marrow, FGF23 mRNA levels, 
suggesting that bone, rather than bone marrow, is an important contributor to severely elevated 
FGF23 levels in this model.  Upon folic acid injection, a model of acute kidney injury, XLKO 
and WT mice exhibited similar degrees of tubulopathy; however, plasma phosphate and FGF23 
elevations were modestly blunted in XLKO males, but not in females, compared to WT 
counterparts.  Our findings suggest that XLαs ablation does not substantially alter FGF23 
production in adult mice but increases susceptibility to adenine-induced kidney injury, causing 
severe FGF23 elevations in plasma and bone. 
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An important hormone regulating phosphate and vitamin D homeostasis is fibroblast growth 
factor 23 (FGF23) (1,2). Pro-FGF23 is synthesized as a 251 amino acid protein in the bone tissue 
by osteoblasts and osteocytes and is cleaved intracellularly to form the mature FGF23 protein, 
which is either secreted intact (iFGF23) or inactivated by another intracellular cleavage step, to 
form the inactive N- and C-terminal fragments (3). iFGF23 then inhibits the reabsorption of 
phosphate from the glomerular filtrate and diminishes the synthesis of the bioactive vitamin D 
metabolite 1,25-dihydroxyvitamin D3 in the renal tubule (4). Dysregulated actions of FGF23 is 
associated with several human genetic and acquired disorders.  For example, patients with X-
linked hypophosphatemic rickets produce excess levels of FGF23 in bone and thus display renal 
phosphate wasting (5). Conversely, patients with familial hyperphosphatemic tumoral calcinosis 
display inactivating mutations in GALNT3 or FGF23 and are therefore deficient for iFGF23 
levels (6). In addition, FGF23 levels in the circulation rise dramatically as a result of renal failure 
(7). Although this elevation is beneficial in early stages of the kidney injury by preventing soft 
tissue mineralization, the highly increased FGF23 levels in end-stage renal disease have been 
found to correlate with the occurrence of left ventricular hypertrophy and the increased risk of 
cardiovascular events (8,9), thus contributing to the morbidity and mortality in patients with 
chronic kidney disease (CKD).  The mechanisms underlying FGF23 production remain 
incompletely defined. 
Osteocytes and osteoblasts in bone are already known to be important producers of FGF23, 
providing a substantial portion of serum FGF23 at baseline and in response to a high phosphate 





















under different conditions, such as in inflammation and in response to kidney injury (1,11-14).  
Mouse studies have shown that bone marrow, which contains hematopoietic and mesenchymal 
stem cells, is capable of producing FGF23 upon blood loss-induced erythropoietin (EPO) 
expression or in response to EPO injection, with a more significant or comparable contribution 
compared to bone, respectively (14-16).  On the other hand, a recent study demonstrated that 
multiple tissues, including bone, contribute to the elevation of FGF23 in a folic acid-induced 
acute kidney injury (AKI) model but observed no elevation of FGF23 mRNA in bone marrow 
(17), suggesting that bone marrow is unlikely to be a source of FGF23 in renal failure.  Relative 
contributions of bone and bone marrow to the excess FGF23 levels in the setting of CKD have 
remained uncertain.  
Production of FGF23 is stimulated by a number of exogenous molecules, including 1,25-
dihydroxyvitamin D, calcium, and leptin (18-20). Recently, inflammatory mediators, which are 
systemically increased in CKD, have also come to the focus of attention as stimulators of FGF23 
synthesis (11,21,22). Another stimulator of osseous FGF23 production is parathyroid hormone 
(PTH), which acts via the stimulatory G protein Gsα, a ubiquitous signaling protein that mediates 
the actions of many hormones, autocrine and paracrine factors, and neurotransmitters via 
generation of cAMP (23-25). The PTH receptor can also couple to other heterotrimeric G protein 
alpha-subunits, including the extra-large variant of Gsα (XLαs) (26-28). XLαs can mimic Gsα 
with respect to cAMP generation and is expressed in bone marrow stromal cells, calvarial 
preosteoblasts, and osteocytes (28-31).  It has been shown that early postnatal mice in which 
XLαs is ablated show hyperphosphatemia with diminished FGF23 levels in bone and in the 
circulation (32-34), indicating that XLαs is required for FGF23 production.  However, unlike the 





















In this study, we investigated the role of XLαs in adult mice with respect to FGF23 
production by examining XLαs knockout mice (XLKO) and wildtype littermates.   Furthermore, 
to determine whether XLαs-mediated mechanisms are involved in kidney injury-induced FGF23 
production, we employed a model of CKD involving the use of adenine-rich diet, as described 
(35).  This model entails tubulointerstitial nephropathy due to the precipitation of highly 
insoluble adenine derivative 2,8-dihydroxyadenine in the renal parenchyma (36). While adult 
XLKO and wildtype (WT) littermates did not show significant differences in baseline plasma 
FGF23 levels, our findings have indicated that XLαs deficiency increases susceptibility to 
adenine-induced kidney injury.  Moreover, we compared the levels of FGF23 mRNA in bone 
and bone marrow, revealing that bone, rather than bone marrow, is a substantial source of plasma 
FGF23 in the adenine-induced kidney injury model.  We also employed the folic acid-induced 
AKI model, in which folic acid causes nephrotoxicity that leads to acute tubular necrosis (37).  
Folic acid injection resulted in a comparable degree of renal failure in XLKO and WT mice 
within 24 hours.  In both CKD and AKI models, we have not detected differences between the 





Mice and Experimental Design 
All animal experiments were conducted in accordance with the accepted standards of the 
Institutional Animal Care and Use Committee, and the studies were approved by The 





















XLKO mice were generated by disrupting the first exon of XLαs on the paternal allele, as 
previously described (38), and maintained in the CD1 background.  WT and XLKO mice had 
free access to water and a standard chow diet (0.9% phosphate, 0.6% calcium). At eight weeks of 
age, mice of each genotype were divided into two groups, of which one group was changed to 
receive an adenine-rich chow diet (0.2% adenine, 0.9% phosphate, 0.6% calcium) for a total 
period of 6 weeks. The mice and the food were weighed, and venous plasma samples were 
obtained from the tail vain on a weekly basis.  Most male mice under the adenine group lost 
more than 25% of their weights before the completion of the study, and therefore, the analyses 
were performed only on female WT and XLKO mice. An aggravated disease progression of 
adenine-induced kidney disease in male compared to female rats has been observed previously 
(39).  This finding is in accordance with observations in humans, as men show a faster 
progression towards end-stage renal disease compared to women before menopause (40), and 
might be caused by higher estrogen and ER-α activation in females (39). The mice were weighed 
weekly and supplemented subcutaneously with lactated ringer solution after 5% body weight loss 
compared to baseline weight at 0 weeks adenine/control-diet to reduce excessive water loss due 
to polyuria. The injected volume was equivalent to 4% of the current mouse weight and was 
given in two portions with four hours in between.  AKI was induced in 12-week-old male and 
female XLKO and WT littermates by injecting 240mg/kg folic acid in sodium bicarbonate 
subcutaneously, as described (41).  Vehicle injection was used as control.  Blood samples were 
taken at baseline and at 2, 8 and 24 hours after injection.  Mice were euthanized after 24 hours, 
























Kidneys were fixed in 10% paraformaldehyde, embedded in paraffin, and serially sectioned at 5 
μm. Hematoxylin and eosin staining was performed using standard protocols. The tissue 
sectioning and staining were conducted at the Endocrine Unit, Massachusetts General Hospital  
Center for Skeletal Research.  
 
Measurement of plasma biochemistries 
Venous plasma samples were collected from tail vain puncture at different timepoints. Plasma 
phosphorous and BUN levels were determined with colorimetric assays, according to the 
manufacturer’s protocols (Phosphate: Abcam Phosphate Assay Kit (Colorimetric); BUN: 
Stanbio™ BUN Liquid Reagent for Diagnostic Set). Plasma FGF23 levels were quantitated by 
using the Mouse/Rat FGF-23 (C-Term) ELISA Kit or the Mouse/Rat FGF-23 (Intact) ELISA Kit 
(both from Immutopics/Quidel). 
 
cDNA synthesis and gene expression analysis 
Cortical bone and bone marrow were separated by removing the epiphysis and metaphysis of the 
femur bone and flushing the diaphysis with PBS.  Bone marrow and cortical bone samples were 
homogenized in Trizol. The total RNA was separated using the ThermoFisher TRIzol™ Reagent 
Kit and precipitated using the Qiagen RNeasy® Plus Mini Kit. Two g RNA from each sample 
was run on a 1.5% Agarose gel to confirm RNA quality. cDNA was synthesized using the New 
England Biolabs ProtoScript II First strand cDNA synthesis kit according to the manufacturer’s 
protocol. qRT-PCR analysis on FGF23 was performed using the Applied biosystems TaqMan 





















VIC (-actin as reference control) and Gapdh-VIC (glyceraldehyde-3-phosphate dehydrogenase 
as reference control).  qRT-PCR analysis on all other genes was performed with specific primers 
and the PowerUp SYBR Green Master Mix (Applied biosystems) with -Actin as a reference 
gene. -Actin (F: 5’-GATCTGGCACCACACCTTCT-3’; R: 5’-
GGGGTGTTGAAGGTCTCAAA-3’), IL-6 (F: 5’-TACCACTTCACAAGTCGGAGGC-3’; R: 
5’-CTGCAAGTGCATCATCGTTGTTC-3’), IL-1 (F: 5’-
GGAGAACCAAGCAACGACAAAATA-3’; R: 5’-TGGGGAACTCTGCAGACTCAAAC-3’), 
Egr-1 (F: 5’-AGCGAACAACCCTATGAGCACC-3’; R: 5’-
ATGGGAGGCAACCGAGTCGTTT-3’). Ratio of bone to bone marrow FGF23 mRNA levels 
(relative to -Actin) were calculated for each study mouse by dividing the bone value to bone 
marrow value at baseline or at 6 weeks of adenine-rich diet. 
 
Statistical analysis 
Leven’s F test was first performed to assess equality of variances between groups. If variances 
were equal, paired or unpaired Student’s t test (two-tailed) was used for determining the 
statistical significance of the difference between two means. Otherwise, Welch’s t test (two-
tailed) was used. For multiple comparisons, Bonferroni correction was performed, i.e the P value 
was multiplied by the number of comparisons. Outliers in each data group were identified by 
using the Grubbs’s test and excluded. Differences in plasma FGF23 values between different 
time points and between adenine-fed or folic acid-injected WT and XLKO mice were analyzed 
by using two-way repeated measures ANOVA.  Pearson correlation coefficient was calculated to 





















was considered statistically significant and represented as follows: *P < 0.05, **P < 0.01, ***P < 
0.001, ****P<0.0001. Analyses were performed by using Prism 6 (GraphPad). 
Results 
XLKO mice develop a more advanced kidney injury upon adenine-rich diet 
To understand the role of XLαs in kidney injury-induced FGF23 production we studied the 
XLαs knockout mice (XLKO).  XLαs expression is monoallelic and occurs paternally in nearly 
all tissues, and XLKO mice carries the targeted gene only on the transcriptionally active paternal 
allele (38).  After confirming the strong reduction of XLs mRNA levels in bone (Fig 1A) and 
bone marrow (Fig 1B) of eight-week old XLKO mice, we measured the levels of total FGF23 
and iFGF23 in the plasma.  At baseline, total FGF23 levels (measured by the C-terminal FGF23 
assay) in XLKO mice tended to be lower than the levels in WT littermates (Fig. 1C).  While this 
result was in line with findings from early postnatal XLKO and WT pups (32), no difference was 
detectable in plasma iFGF23 levels between the two genotypes (Fig. 1D).  In order to investigate 
whether XLαs is required for the FGF23 synthesis in CKD, we fed eight-week old XLKO and 
WT littermates a diet containing 0.2% adenine, as described previously (35,42).  Many of the 
male XLKO mice had to be euthanized due to excessive weight loss two weeks after the start of 
the adenine diet (Fig 1E), and therefore, we had to limit our data collection to female XLKO and 
WT littermates.  Among female mice, only one WT and one XLKO had to be excluded from the 
study due to excessive weight loss (Fig. 1F).  As soon as one week after introducing the adenine-
rich diet, pale spots could be found grossly on the kidney surface (Fig. 2A).  After 6 weeks of 
adenine-rich diet, the whole kidneys appeared pale and showed morphological signs of atrophy 
with an irregular surface and a reduced size (Fig. 2B). The H&E staining of renal sections 





















of tubulopathy in XLKO than in WT kidneys (Fig. 2C).  A significant increase in plasma 
phosphate levels was observed in both XLKO and WT littermates after six weeks of the adenine 
diet (Fig. 2D).  In addition, blood urea nitrogen (BUN) levels were elevated compared to 
baseline in both genotypes, and the elevation was significantly more pronounced in XLKO than 
in WT littermates (Fig. 2E).  These findings confirmed the anticipated effect of adenine-rich diet 
on the kidney and suggested that XLKO mice had more advanced kidney injury compared to WT 
littermates.  We found a slightly decreased adenine-rich food intake in XLKO mice compared to 
WT littermates (WT control diet: 0.73±0.1g; WT adenine diet: 0.78±0.05g; XLKO control diet: 
0.62±0.17g; XLKO adenine diet: 0.42±0.13g; values reflect the consumed amount of food per 
day per gram mouse weight), thus making it unlikely that the more advanced kidney injury in 
XLKO mice reflected increased consumption of the adenine-rich diet.   
 
More advanced renal injury in XLKO mice is associated with higher plasma FGF23 
levels 
To characterize the FGF23 synthesis, we measured plasma total FGF23 levels, finding out 
that an elevation was detectable as soon as one week after introducing the adenine-rich diet in 
both XLKO (2,251 ± 766.7 pg/ml) and WT (994.2 ± 232.4 pg/ml) mice (Fig. 3A).  At 6 weeks, 
total FGF23 levels were markedly elevated, with higher levels in XLKO than WT 
(104,206±21,741 vs. 18,430±3,379 pg/ml, p<0.0001; Fig. 3A).  A mild increase of total FGF23 
levels were also observed in control diet-fed animals (Fig. 3B).  Plasma iFGF23 also measured 
higher in both WT and XLKO mice fed the adenine-rich diet compared to control diet for six 
weeks, with significantly higher levels in XLKO than WT mice (Fig. 3C).  We then examined 





















correlation was observed in either genotype (Fig. 3D).  At 6 weeks, WT mice continued to show 
no linear correlation between plasma total FGF23 and phosphate, whereas XLKO mice displayed 
a statistically significant positive linear correlation (Fig. 3E).  When all data – baseline and 6 
weeks of adenine diet – are analyzed together, total FGF23 appeared to be linearly correlated 
with plasma phosphate only in XLKO mice (Fig. 3F).  Due to the wide variation of FGF23 
values between baseline and 6 weeks of adenine diet, we then reperformed the linear regression 
and correlation analysis after semi-log transformation of the data, i.e. logarithm of FGF23 vs. 
phosphate.  This analysis indicated a positive correlation in both WT and XLKO mice, and 
furthermore, the linear relationship between log(FGF23) and phosphate in WT mice appeared to 
be comparable to that in XLKO mice according to the statistical analysis of the difference 
between the slopes (Fig. 3G). 
 
Bone is an important contributor to plasma FGF23 levels in CKD 
Both osteoblasts/osteocytes and bone marrow have been described as significant producers of 
FGF23 (1,14,43,44). In order to characterize the synthesis of FGF23 in more detail, we extracted 
femur bone and bone marrow samples from XLKO and WT mice after 6 weeks of adenine-rich 
or control diet. Consistent with the plasma FGF23 levels, qRT-PCR analysis revealed increased 
FGF23 mRNA levels in femur bone (Fig. 4A) and bone marrow samples (Fig. 4B) of mice fed 
the adenine-rich diet. The values obtained from the femurs of adenine-fed XLKO mice showed 
wide variation, and therefore, the difference between these mice and the control diet-fed XLKO 
mice did not reach statistical significance (Fig 4A). In contrast, the increases observed in bone 
marrow were significant in both WT and XLKO littermates (Fig, 4B). These findings were 





















these experiments strongly suggested that the levels of FGF23 mRNA are markedly higher in 
bone than in bone marrow.  Calculating the bone-to-bone marrow ratio in individual mice of 
either genotype, we found that, at baseline, the mean FGF23 mRNA level relative to -actin was 
28.6 ± 8.3 (95% confidence interval: 7.3-49.8) times higher in bone than in bone marrow.  Six 
weeks after the adenine-rich diet, the FGF23 mRNA level continued to be dramatically higher in 
bone (Fig. 4E), with the mean bone-to-bone marrow ratio being 20.5 ± 7.7 (95% confidence 
interval: 1.5-39.4). When FGF23 mRNA was quantified relative to Gapdh, the level in bone 
following the six-week adenine-rich diet was 31.4 ± 10.5-fold (95% confidence interval: 5.8-
56.9) higher than in bone marrow (Fig. 4E).  To further investigate the contributions of bone and 
bone marrow to the plasma FGF23 levels, we analyzed the relationship between plasma FGF23 
and tissue FGF23 mRNA levels.  A positive correlation was observed in WT animals between 
plasma FGF23 and both bone (Fig. 5A) and bone marrow FGF23 mRNA levels (Fig. 5D).  In 
contrast, a statistically significant correlation existed in XLKO animals only between plasma 
FGF23 and bone FGF23 mRNA levels (Fig. 5B, E).  When the analysis was performed after 
pooling the values from both genotypes, plasma FGF23 correlated significantly with FGF23 
mRNA in bone, but not in bone marrow (Fig. 5C, F).  However, analyzing the logarithm of 
plasma FGF23 levels against bone marrow FGF23 mRNA levels, we detected a positive 
correlation in XLKO mice, as well as in pooled data from both of the genotypes (Fig. 5G, H). 
 
Local inflammation is unlikely to drive the excess FGF23 production in bone and bone 
marrow in CKD 
Inflammatory mediators have been shown to stimulate FGF23 expression (21,45,46). As 





















increase of FGF23 in bone and bone marrow samples reflect increased inflammation in these 
tissues. Analysis of inflammation markers isolated after 6 weeks of adenine-rich diet revealed a 
tendency of IL-1 mRNA levels to rise in XLKO (bone: 1.7 ± 0.29-fold; p=0.10; bone marrow: 
1.84 ± 0.3-fold; p=0.06) but not in WT mice compared to control diet (Fig. 6A, B). The mRNA 
levels of IL6, which has been reported as an essential mediator of adenine-rich diet-induced 
FGF23 elevation (21), were modestly diminished in both bone and bone marrow of adenine-fed 
WT mice compared to control diet-fed WT mice (Fig. 6A, B).  However, no significant 
differences were detected in IL6 mRNA levels in XLKO bone and bone marrow samples 
between control and adenine-rich diet (Fig. 6A, B).  In contrast, both IL1 and IL6 and mRNA 
levels were markedly elevated in whole kidneys from WT and XLKO mice (Fig. 6C), verifying 
that the adenine-induced kidney injury was associated with increased renal inflammation.   
 
Renal induction of FGF23 expression as a result of adenine-rich diet 
It has recently been shown that FGF23 expression is induced in kidney tissue upon kidney 
injury (12,13). We thus sought to determine the FGF23 expression in WT and XLKO kidneys.  
While no FGF23 mRNA could be detected in whole kidneys of mice receiving the control diet, 
FGF23 mRNA was readily detectable in this tissue one week after introducing the adenine-diet 
in both genotypes and throughout the six-week experimental period (Fig. 7A, B).  The actions of 
FGF23 in the kidneys are mediated by the activation of different pathways.  One of these 
pathways initiates the suppression of renal Na/Pi cotransporters by increasing the renal 
expression of Egr1 through activation of the ERK1/2 signaling pathway (47). qRT-PCR 
experiments revealed an enhancement of renal Egr1 expression as soon as one week after 





















in kidney correlated positively with plasma FGF23 levels (Fig. 7E), whereas no correlation was 
detected between renal Egr1 and FGF23 mRNA levels (Fig. 7F). 
 
Folic acid induces comparable degrees of AKI in XLKO and WT mice with no apparent 
induction of renal FGF23 expression 
To understand whether the increased susceptibility of XLKO mice to renal injury is specific 
to adenine-rich diet, we examined the effects of folic acid, an agent that leads to acute kidney 
injury.  Within 24 hours after folic acid injection, plasma FGF23 levels rise markedly (41), and 
FGF23 mRNA levels increase in multiple tissues, including bone but not bone marrow (17). As 
expected, we observed a gradual increase of BUN in folic acid-injected female and male mice, 
and the levels were comparable at each time point between WT and XLKO (Fig. 8B, E), 
suggesting a similar degree of renal injury in both genotypes.  Plasma phosphate also increased 
similarly in WT and XLKO mice, with modestly lower levels in XLKO males compared to WT 
males 24 hours after the injection (Fig. 8A, D).  Plasma total FGF23 also rose gradually without 
significant differences between genotypes; however, male XLKO mice showed significantly 
lower FGF23 levels than WT males at 24 hours (Fig. 8C, F).  Linear regression analysis of total 
FGF23 and phosphate levels did not reveal any significant differences between WT and XLKO 
mice, showing positive linear correlations (Fig. 9A, C).  However, on semi-log transformation of 
data, the slope of the regression line was steeper in XLKO males, but not in females, than their 
WT counterparts (Fig. 9B, D), suggesting that phosphate might have a greater magnitude of 
effect on total FGF23 levels in XLKO males in the setting of acute kidney injury. 
We also analyzed the kidneys of folic acid-injected mice with respect to the expression levels 





















detect renal FGF23 expression in control or folic acid-injected mice, regardless of the genotype.  
IL6 mRNA levels in kidneys of folic acid-injected mice, on the other hand, were elevated (Fig. 
10A, B); however, the elevation in WT females was not statistically significant (Fig. 10A).  
Renal IL1 mRNA levels rose mildly in WT and XLKO females in response to folic acid-
injection, but the differences were not statistically significant (Fig. 10C).  WT males, but not 
XLKO males, displayed a slight, statistically significant elevation of renal IL1 mRNA (Fig. 
10D).  Renal Egr1 mRNA levels were elevated in folic acid-injected WT and XLKO mice 




Based on our recent observations of reduced FGF23 plasma levels in early postnatal XLKO 
mice, and based on the finding that XLαs is expressed in adult bone, we investigated the role of 
this protein in renal injury-induced FGF23 production.  We used an established model of CKD 
involving an 0.2% adenine-containing diet.  We chose to begin the diet in 8 week-old mice, 
because the initial study that established this protocol in mice, as well as many pursuant studies, 
had employed mice at this age and been able to reliably detect increases in FGF23 levels (35).  
Although mice at this age have typically not reached skeletal maturity, this is unlikely to 
confound our results, given that the control diet-fed WT and XLKO mice showed only a minor 
increase in their FGF23 levels over the 6-week treatment period.  In addition, we also measured 
the difference in plasma phosphate levels in control diet-fed mice between 8 weeks and 14 weeks 
(i.e. the end-point of our study), and revealed that, in keeping with findings in pediatric age 





















0.572±0.14mM and -0.323±0.1mM in 14 week old control-diet fed females compared to 8 week 
old females, respectively).  This finding indicates that the adenine diet-induced elevation of 
plasma phosphate at 6 weeks was in fact more pronounced than that assessed when comparing to 
the baseline (0 week). 
Consistent with the previous literature, male mice fed the adenine-rich diet developed renal 
failure more severely than female mice and, therefore, had to be excluded from the study due to 
excessive weight loss before the end of the six-week study period.  Morphological and 
histological analyses of data from female mice, as well as BUN levels, indicated a more 
progressive kidney disease in XLKO compared to WT littermates.  It appears likely that adenine, 
rather than an intrinsic kidney pathology, is responsible for the enhanced renal injury in XLKO 
mice, considering that these mice did not display a similarly increased susceptibility to renal 
injury upon folic acid injection. 
When adenine-phosphoribosyltransferase, which converts adenine to adenosine-
monophosphate and inorganic pyrophosphate, is defective or when adenine concentration 
exceeds enzymatic capacity, adenine becomes increasingly metabolized by xanthine 
dehydrogenase, which converts adenine into the highly insoluble derivate 2,8-dihydroxyadenine. 
This molecule precipitates in the renal parenchyma, causing a crystalline nephropathy (36). 
XLKO phenotype is characterized by poor adaptation to feeding, early postnatal lethality, and 
defective glucose and energy metabolism. Furthermore, XLKO mice are lean, hypermetabolic, 
and show increased sympathetic nervous system activity (38,49). This hypermetabolic state 
might cause an increase in turnover of adenine by xanthine dehydrogenase, producing higher 
concentrations of its insoluble derivates and, in turn, leading to a faster progression of kidney 





















WT pancreatic tissue (50), and depletion of XLαs leads to a pancreatic endocrine dysfunction 
(38), XLαs deficiency in pancreas might be another reason for the dissimilar progression of CKD 
in WT and XLKO mice. In addition, the ability to accumulate adenosine and hypoxanthine in 
adipose tissue (51) might act as an additional buffering mechanism for the WT animals, which 
have larger adipose tissue than their XLKO littermates.  
Contrary to previous observations of significantly reduced plasma FGF23 levels in young 
XLKO pups, we detected only a slight reduction in total FGF23 plasma levels in eight-week old 
XLKO mice.  It may be that the actions of XLαs in FGF23 synthesis are compensated by other 
signaling proteins in adults.  It is also possible that the systemic alterations in adult XLKO mice 
may mask or counteract the FGF23-related phenotype resulting from the skeletal XLαs 
deficiency. 
We did not find a significant correlation at baseline between plasma total FGF23 and 
phosphate levels in WT or XLKO mice.  Note that a correlation between plasma FGF23 and 
phosphate levels at baseline has not been consistently observed, and the data remain conflicting 
(52-54). The positive correlation between plasma FGF23 and phosphate levels in adenine-fed 
XLKO mice, as opposed to WT mice, may reflect the more severe renal injury and higher FGF23 
levels in XLKO mice.  However, on semi-log transformation of the entire data set, we could 
detect a significant positive correlation in both genotypes, and the relationship between plasma 
total FGF23 and phosphate did not appear to differ between XLKO and WT.  We could not 
obtain a higher degree of renal injury, which could have perhaps revealed the effect of XLαs 
deficiency, if any, on the plasma FGF23 response to kidney injury.  Nonetheless, XLKO mice 





















to FGF23 levels by providing a more advanced adenine-induced renal injury model than WT 
mice and a wide range of plasma FGF23 values with severely elevated levels. 
In folic acid injection experiments, we were able to study both males and females and 
observed a comparable degree of renal failure in XLKO and WT mice.  Although the 
relationship between plasma phosphate and total FGF23 levels were not different between the 
two genotypes of mice, there was a modest blunting of the FGF23 elevation in XLKO males, but 
not females, 24 hours after folic acid injection.  This finding may reflect the mild blunting of the 
plasma phosphate elevation in those mice at the same time point.  We currently have no 
explanation for the mildly blunted increase in plasma phosphate and FGF23 levels in folic acid-
injected XLKO males.  However, although BUN levels were comparable in XLKO and WT 
males, the renal inflammation markers in XLKO males did not appear to be as robustly increased 
as in WT males, suggesting a lower degree of renal injury in XLKO than in WT males.    
Upon hypoxia-stimulated EPO production, bone marrow has been found to be another 
important producer of FGF23 in AKI (14,15,44).  In our adenine-induced CKD model, FGF23 
mRNA levels increased in both bone and bone marrow, confirming that FGF23 production is 
stimulated in the latter, as well as in bone.  However, we found FGF23 expression to be 
especially high in bon  compared to bone marrow, both at baseline and six weeks after the 
adenine-rich diet.  Although our quantitative RT-PCR analysis was not designed to measure 
absolute RNA amount, the dramatically higher FGF23 levels in bone than in bone marrow was 
detected by using two different house-keeping genes as reference control.  Moreover, the 
positive linear correlation in WT mice between plasma FGF23 and bone marrow FGF23 mRNA 
levels was not detected in XLKO mice, which showed markedly high levels of plasma FGF23 





















transformation of data.  These results may suggest that the exceedingly high levels of plasma 
FGF23 reflect production in bone rather than in bone marrow.  Nevertheless, our conclusion is 
based on FGF23 mRNA measurements, and we realize that the vast difference between the 
levels of bone and bone marrow FGF23 mRNA may not necessarily reflect the differences in 
protein levels.  While this possibility is important to consider, the FGF23 mRNA expression 
changes observed in previous studies were concordant with protein level alterations (14,15,44).  
Moreover, in agreement with our findings, a recent study showed that the serum and bone 
FGF23 elevation in a similar adenine-induced renal injury model is reduced by ~90% in mice 
with conditional ablation of FGF23 in mature osteoblast/osteocytes (55). 
Inflammation is an important regulator of FGF23 production, and IL6 has been shown as an 
important stimulator of FGF23 production in response to adenine-induced nephropathy 
(11,21,22).  We found unaltered IL1 mRNA levels and modestly diminished IL6 mRNA levels 
in bone and bone marrow samples from WT mice following 6 weeks of adenine-rich diet.  Given 
that the levels of FGF23 mRNA in these tissues significantly rose during this time, our findings 
suggest that local inflammation has a minor role in FGF23 production in this model of CKD.  In 
XLKO bone and bone marrow samples, however, the alterations observed in the levels of these 
inflammatory markers were different, with mildly increased levels of IL1 mRNA and unaltered 
levels of IL6 mRNA.  This tendency of increased local inflammation in XLKO bone following 
the adenine diet may reflect the greater degree of renal injury in those mice than in WT mice.  
Our findings cannot rule out the possibility that full-blown inflammation in bone and/or bone 
marrow, which could develop as a result of highly advanced renal injury, contributes to the 





















Recently it has been shown that the renal tubular epithelial cells also express FGF23 mRNA 
and protein in response to injury (12,13).  Corroborating those previous observations, our data 
also indicate that the ectopic renal FGF23 expression is detectable concurrently with the excess 
FGF23 levels in plasma, i.e. soon after the impairment of renal function by the adenine-rich diet.  
However, the FGF23 mRNA found in kidney did not correlate with plasma FGF23 levels.  This 
finding suggests that mechanisms governing the induction of FGF23 expression in kidney differ 
from those underlying the overproduction of this hormone in osseous tissues.  Interestingly, renal 
expression of Egr1, which translates the action of FGF23 (47), correlated with plasma FGF23 
levels, but not with renal FGF23 mRNA levels, strongly suggesting that the renal Egr1-response 
reflects global FGF23 elevation. 
Despite evidence of renal injury with elevated BUN and phosphate levels, the folic acid 
injection did not lead to an induction of FGF23 expression in kidney.  It is also possible that a 
longer duration of injury is required for the induction of renal FGF23 expression or that the latter 
requires a specific type of kidney injury, such as the one generated by adenine.  Our finding, 
however, contrasts the data in a recent report, in which folic acid injection was stated, but not 
shown, to induce ectopic renal FGF23 expression (17).  The latter study used the same dose and 
administration route of folic acid but employed a different genetic background (C57Bl/6J), 
which could perhaps explain the discrepancy.  With respect to renal Egr1 mRNA levels in our 
AKI model, we did not detect an elevation in folic acid-injected XLKO males compared to 
vehicle-injected XLKO males.  This may reflect the blunted increase of plasma FGF23 levels in 
those mice. 
In summary, we examined the role of XLαs in adult mice regarding kidney injury-induced 





















induced nephropathy, and that bone, rather than bone marrow, is a major source of excess FGF23 
resulting from adenine-induced renal injury.  Unlike the findings in early postnatal mice, our 
study did not reveal any evidence that XLαs ablation significantly impairs FGF23 production in 
adult mice. 
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Figure 1.  XLs and FGF23 levels in WT and XLKO mice, as well as their weights and 
survival during adenine-rich diet. 
Eight-week old WT and XLKO mice were euthanized and XLs-mRNA levels were measured 
in bone (A) and bone marrow tissue (B). 
Plasma samples from 8 week-old WT and XLKO females were collected and levels of total (C) 
and intact (D) FGF23 were determined. Unpaired Student’s t-test (two-tailed) was used for 
statistical comparison. Welch’s Test was used for unequal variances.  
(E) Females and males were weighed on a weekly basis and the weight progression was 
compared between the genotypes and the diets. Figure (F) shows the survival data of males and 
females of both genotypes during the adenine-rich diet.  
(A) WT n=3, XLKO n=3; (B) WT n=3, XLKO n=3 
(C) WT n=18, XLKO n=23; (D) WT n=9, XLKO n=11 
(E) female WT adenine n=12, control n=10; females XLKO adenine n=13, control n=12; male 
WT adenine n=4, control n=6; male XLKO adenine n=8, control n=7;  
(F) females n=25, males n=12 
 
Figure 2. The effect of the adenine-rich diet on kidneys. 
(A) Kidneys from three female WT and three female XLKO mice we harvested at 0, 1, or 2 
weeks of adenine diet. Pale spots on the kidney surface display an early onset of the kidney 
damage. Morphological comparison reveals a faster progressing kidney injury in XLKO mice 
starting at 1 week of Adenine Diet.  At 6 weeks (B), kidneys of adenine-fed mice were shrunk 





















dilation upon six weeks of adenine diet with more pronounced kidney damage in the XLKO 
mice compared to WT mice. (For B, C) Six WT mice receiving control diet, six WT mice 
receiving adenine diet, seven XLKO mice receiving control diet and nine XLKO mice receiving 
adenine diet were compared for histological and morphological analysis. Representative 
histology sections are shown. (D, E) Plasma phosphate and BUN levels in WT and XLKO mice 
following adenine-rich diet.  Plasma samples were collected from WT and XLKO mice before 
and after 6 weeks of adenine or control diet. BUN (D) and Phosphate (E) levels were obtained. 
Unpaired Student’s t-test (two-tailed) was used, with or without Welch’s Test (for unequal 
variances), followed by Bonferroni correction of the p values for multiple comparisons. (D) 0 
week WT n=11, XLKO=11; 6 week WT n=11, XLKO=11; (E) 0 week WT n=14, XLKO=12; 6 
week WT n=11, XLKO=11;  
 
Figure 3. Time-course of plasma FGF23 elevation, and the relationship between FGF23, 
plasma phosphate and BUN. 
8 week-old WT and XLKO mice were fed with 0.2% adenine-rich or control diet for 6 weeks. 
Plasma samples were collected at different timepoints. (A) The time course of total FGF23 is 
shown in WT (blue) and XLKO (red) plasma samples at 0, 1, 2, 4 and 6 weeks of adenine (A) 
and control diet (B). Two-way ANOVA multiple comparison analysis was used for statistical 
analysis. (C) iFGF23 levels are shown after 6 weeks of control or adenine diet. Unpaired 
Student’s t-test (two-tailed) was used for statistical comparison between the genotypes. Linear 
regression analysis was performed between total plasma FGF23 and phosphate in WT and 
XLKO mice before (0 wk, D) and after six weeks of adenine diet (E). Both timepoints were 





















after semi-log transformation of total plasma FGF23 (G). The Pearson correlation coefficient 
was calculated. (A) WT adenine n=8, XLKO adenine n=10; (B) WT control n=9, XLKO control 
n=12; (C) Control WT n=10, XLKO=12; Adenine WT n=9, XLKO=11; (D) WT n=9, XLKO 
n=10; (E) WT n=9, XLKO n=10; (F, G) WT n=18, XLKO n=20. 
 
Figure 4. Bone and bone marrow FGF23 mRNA levels in response to adenine-rich diet. 
8 week-old WT and XLKO mice were fed with 0.2% adenine or control diet for 6 weeks.  
Cortical bone (A, C) and bone marrow (B, D) tissue samples were collected and FGF23 mRNA 
levels were determined at 6 weeks by using beta-actin (A, B) or GAPDH (C, D) as reference 
control. Unpaired Student’s t-test (two-tailed) was used for statistical analysis. Welch’s Test was 
used for unequal variances. (E) Ratio of bone-to-bone marrow FGF23 mRNA level after 6-weeks 
of adenine diet, measured relative to either -actin or GAPDH in individual mice from both WT 
and XLKO groups.  (A) Control WT n=5, XLKO=5; Adenine WT n=4, XLKO=7; (B) Control 
WT n=4, XLKO=6; Adenine WT n=5, XLKO=9; (C) Control WT n=5, XLKO=5; Adenine WT 
n=4, XLKO=7; (D) Control WT n=5, XLKO=5; Adenine WT n=5, XLKO=7; (E) n=7 for both 
groups. 
 
Figure 5.  The relationship between plasma FGF23 and bone or bone marrow FGF23 
mRNA levels in WT and XLKO mice. 
Linear regression analysis was performed between plasma FGF23 and tissue FGF23 mRNA 
expression in bone (A-C) and bone marrow (D-F), determining the Pearson correlation 
coefficient. Bone marrow FGF23 was compared to log (plasma FGF23) in XLKO (G) and both 





















coefficient. (A) WT n=9 (Control n=5, Adenine n=4), (B) XLKO n=11 (Control n=5, Adenine 
n=6); (C) WT + XLKO n=20, (D) WT n=9 (Control n=4, Adenine n=5), (E) XLKO n=14 
(Control n=6, Adenine n=8), (F) WT + XLKO n=23, (G) XLKO n=14 (Control n=6, Adenine 
n=8), (H) WT + XLKO n=23. 
 
Figure 6. Markers of inflammation in bone, bone marrow and kidney tissue following 6 
weeks of adenine-rich diet. 
Eight-week old WT and XLKO mice were fed with 0.2% adenine (gray bars) or control (black 
bars) diet for 6 weeks. Cortical bone (A), bone marrow (B) and kidney samples (C) were 
collected and IL1 and IL6 mRNA levels were determined using -actin as reference control. 
Unpaired Student’s t-test (two-tailed) was used for statistical comparisons. Welch’s Test was 
used for unequal variances. 
(A) Control WT n=5, XLKO=5; Adenine WT n=5, XLKO=7; (B) Control WT n=5, XLKO=6; 
Adenine WT n=6, XLKO=9; (C) Control WT n=10, XLKO=12; Adenine WT n=9, XLKO=11. 
 
Figure 7. Adenine-induced alterations in kidney, including the induction of FGF23 mRNA 
expression. 
Eight-week old WT and XLKO mice were fed with 0.2% adenine (gray bars) or control (black 
bars) diet and kidney samples were collected after 1, 2 or 6 weeks. FGF23 (A, B) and Egr (C, D) 
mRNA expression levels were determined using -actin as reference control. ND = none 
detected. Linear relationship between kidney Egr1 mRNA and total plasma FGF23 levels (E) or 
kidney FGF23 mRNA expression (F) was examined by correlation analysis using the Pearson 





















comparisons. Welch’s Test was used for unequal variances. (A) WT: 1 week Adenine n=3; 2 
week Adenine n=3; 6 week Adenine n=10; (B) XLKO: 1 week Adenine n=3; 2 week Adenine 
n=3; 6 week Adenine n=10; (C) WT: 1 week Adenine/Control n=3; 2 week Adenine/Control 
n=3; 6 week Adenine/Control n=9; (D) XLKO: 1 week Adenine/Control n=3; 2 week 
Adenine/Control n=3; 6 week Adenine n=9; 6 week Control n=11; (E) n=17 (WT n=8, XLKO 
n=9); (F) n=17 (WT n=8, XLKO n=9). 
 
Figure 8. Plasma phosphate, BUN, and plasma FGF23 dynamics after folic acid-induced 
acute kidney injury. 
12-week old WT and XLKO males and females were injected subcutaneously with folic acid and 
euthanized after 24 hours. Blood samples were collected 0, 2, 8 and 24 hours after folic acid 
injection and levels of plasma phosphate (A, D), BUN (B, E) and FGF23 (C, F) were 
determined. Two-way ANOVA multiple comparison analysis was used for statistical analysis. 
(A) WT n=10, XLKO n=10; (B) WT n=10, XLKO n=10; (C) WT n=9, XLKO n=10; (D) WT 
n=11, XLKO n=8; (E) WT n=11, XLKO n=8; (F) WT n=11, XLKO n=7. 
 
Figure 9. The relationship between plasma FGF23 and phosphate levels after folic acid-
induced acute kidney injury. 
12-week old WT and XLKO males and females were injected subcutaneously with folic acid and 
euthanized after 24 hours. Blood samples were collected 0, 2, 8 and 24 hours after folic acid 
injection. Levels of plasma FGF23 and phosphate were obtained. Data points of all four 





















correlation coefficient (A, C). Panels B and D display the semilogarithmic graphs of data in 
panels A and C.  
(A, B) WT n=36 (9 mice), XLKO n=40 (10 mice); (C, D) WT n=44 (11 mice), XLKO n=28 (7 
mice). 
 
Figure 10. Folic acid-induced alterations of inflammation markers and Egr1 expression in 
kidney. 
12-week old WT and XLKO males and females were injected subcutaneously with vehicle 
(control) or folic acid (FA) and euthanized after 24 hours. Kidney samples were collected and 
mRNA expression levels of IL6 (A, D), IL1 (B, E) and EGR1 (C, F) were determined using -
Actin as reference control. Unpaired Student’s t-test (two-tailed) was used for statistical 
comparisons. Welch’s Test was used for unequal variances, followed by Bonferroni correction of 
p values. 
(A) WT control n=8, FA n=9; XLKO control n=10, FA n=9; (B) WT control n=9, FA n=10; 
XLKO control n=10, FA n=8; (C) WT control n=8, FA n=11; XLKO control n=9, FA n=8; (D) 
WT control n=9, FA n=11; XLKO control n=11, FA n=9; (E) WT control n=8, FA n=10; XLKO 
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